Lily's Story | Colon Cancer

Life can be unpredictable. Lily Hickey, People Experience Lead in Commercial Oncology, experienced this firsthand when she was diagnosed with stage 3 colon cancer.

Pfizer Going 'All In' on Obesity Drug Development

Pfizer is going "all in" to develop its experimental obesity drug and the company could start a late-stage study of its drug, danuglipron, in the second half of this year.

Pfizer and Our CEO Albert Bourla Recognized by TIME, Fortune

Take a look to see where Pfizer, and our CEO Albert Bourla, landed on a variety of lists-including TIME's 100 Most Influential Companies and Forbes America's Dream Employers-recognizing both our work in the lab and in the office.

In Search of a New Hemophilia Treatment

Despite significant advancements in hemophilia treatments over the past several decades, a fundamental challenge remains for many patients: balancing management of the disorder while maintaining regular day-to-day activities.

Items of Interest

Have a Question About Your Benefits?

Visit the Pfizer Benefits Center for answers!

Visit the
Community Corner

Connect with former colleagues, view recent retirements and more!

Connected. Active. Involved.

Welcome to the official website for retirees of Pfizer and its legacy organizations.

Pfizer News

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
February 04, 2025
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
February 03, 2025
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
January 28, 2025
Pfizer's BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
January 25, 2025
Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-NaÏve, High-Risk Non-Muscle Invasive Bladder Cancer
January 10, 2025
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 06, 2025
U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
December 20, 2024
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
December 19, 2024
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
December 17, 2024
Pfizer Declares First-Quarter 2025 Dividend
December 12, 2024
Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
December 12, 2024
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
December 10, 2024
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
December 10, 2024
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
December 05, 2024
Pfizer Announces New Chief Scientific Officer and President, Research & Development
November 20, 2024
European Commission Approves Pfizer's HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
November 20, 2024
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 14, 2024

Click here view all Pfizer News stories.

Join the Pfizer Plus Community Corner

When you join the PfizerPlus.com community, you can get access to our special “member’s only” features including:

  • Member Only Content
  • Email Updates
  • PfizerPlus.com Community